Key points are not available for this paper at this time.
Benralizumab is an eosinophil-depleting anti-interleukin-5 receptor α monoclonal antibody. The efficacy and safety of benralizumab in patients with eosinophilic esophagitis are unclear.
Rothenberg et al. (Wed,) studied this question.